Seasonal Influenza Clinical Trial
Official title:
A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age
This study will evaluate the safety and immunogenicity in healthy children and adolescents after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.
Status | Completed |
Enrollment | 3116 |
Est. completion date | September 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 3 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Males and females aged 3 to 17 years, in good health as determined by medical history, physical examination and clinical judgment of the investigator - Documented consent provided by parents or legal guardians - For individuals 8 years of age and older, informed assent to participate in the study after the nature of the study had been explained to them in terms they could understand - Individuals and parents/guardians who were able to comply with all study procedures and were available for all clinic visits scheduled in the study Exclusion Criteria: - Parents or legal guardians and individuals who are not able to comprehend and to follow all required study procedures for the whole period of the study - Parents or legal guardians and individuals providing assent who do not consent to the retention of the subject's serum samples after study completion - Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may have interfered with the subject's ability to participate in the study - Individuals with history or any illness that, in the opinion of the investigator, might have interfered with the results of the study or posed additional risk to the subjects due to participation in the study - History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, latex, to any excipients, and to eggs (including ovalbumin), chicken protein, influenza viral protein, kanamycin, neomycin sulphate, cetyltrimethylammonium bromide (CTAB), polysorbate 80, neomycin, polymixin, formaldehyde, thimerosal, beta propiolactone, or nonoxynol-9 - History of any serious disease, such as: 1. cancer 2. history of serious chronic, rheumatologic, neurologic and hematologic diseases 3. history of underlying medical condition such as inborn errors of metabolism - Known or suspected impairment/alteration of immune function, including: 1. chronic use of oral steroids within 60 days prior to Visit 1 (use of inhaled, intranasal, or topical corticosteroids is allowed) 2. receipt of immunostimulants within 60 days prior to Visit 1 3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within 3 months prior to Visit 1 or planned during the full length of the study 4. HIV infection or HIV-related disease - Pregnant or breast-feeding female and any positive or indeterminate pregnancy test - Received an influenza vaccine within 6 months prior to Visit 1 - Laboratory-confirmed or suspected influenza disease within 6 months prior to Visit 1 - Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study - Experienced a fever and/or any acute illness within 3 days prior to each study vaccination |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Colombia | Centro de Atención e Investigación Medica - CAIMED | Carrera 42A # 17-50, Bogotá | |
Mexico | Clinical research institute ,S.C(CRI), Blvd Manuel Avila Camacho 1994 Consultorio 1103 Col. San Lucas Tepetlacalco, C.P.54055 Tlalnepantla | Estado de México | |
Panama | Clinica Hospital San Fernando, Floor 4 Office 419 via España las Sabanas | Panamá | |
Panama | Consultorios America Floor 2 Office 201-1, Via España Vista Hermosa | Panamá | |
Panama | Consultorios Medicos San Judas Tadeo Principal Street, Floor 5 Office 507, Villa Lucre | Panamá | |
Panama | Centro de Salud Magally Ruiz, Street Bolivar | Panama - La Chorrera | |
Philippines | Research Institute for Tropical Medicine, Department of Health Compound, FILINVEST Corporate City | Alabang, Muntinlupa City | |
Philippines | University of the East Ramon Magsaysay Medical Center, 64 Aurora Boulevard | Barangay Dona Imelda Quezon City | |
Philippines | De La Salle Health Sciences Institute | Dasmarinas Cavite | |
Philippines | Research Institute for Tropical Medicine, Department of Health Compound | FILINVEST Corporate City, Alabang | Muntinlupa City |
Philippines | Mary Chiles General Hospital, 667 Gastambide St. Sampaloc | Manila | |
Philippines | Philippine Children's Medical Center, Quezon Avenue corner Agham Road | Quezon City | |
Philippines | Philippine General Hospital | Taft Avenue, Manila | Manila |
Lead Sponsor | Collaborator |
---|---|
Novartis Vaccines |
Colombia, Mexico, Panama, Philippines,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of the Percentage of Subjects Achieving Seroconversion | The non-inferiority of the antibody responses of investigational TIV compared to control TIV assessed in terms of the percentage of subjects achieving seroconversion, against the three homologous vaccine strains,in children 3 to 8 years of age, at 21 days after last vaccination. Seroconversion was defined as a pre-vaccination haemagglutinin inhibition (HI) titer <1:10 and post-vaccination HI titer =1:40 or as a pre-vaccination HI titer =1:10 and at minimum four-fold rise in post-vaccination antibody titer |
Day 22 for non-naive/Day 50 for naive subjects | No |
Primary | Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of Post Vaccination Geometric Mean Titers (GMTs) | The non-inferiority of the antibody responses of investigational TIV compared to control vaccine assessed in terms of post vaccination GMTs, at 21 days after last vaccination against the three homologous vaccine strains in 3 to 8 year old children. | Day 22 for non-naive/Day 50 for naive subjects | No |
Secondary | Percentages of Subjects Achieving HI Titers =40 Following Vaccination With Investigational TIV or Control Vaccine. | The percentages of 3 to 8 year old subjects achieving HI titers =40 after receiving either one or two doses of investigational TIV or control vaccine, 21 days after last vaccination, are reported. This criterion according to the US (CBER)guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers =40, is =70%. |
Day 22 for non-naive/Day 50 for naive subjects | No |
Secondary | Percentages of Subjects With Seroconversion in Antibody Titers Following Vaccination With Investigational TIV or Control Vaccine | The percentages of 3 to 8 years-old subjects achieving seroconversion in HI antibody titers after receiving either one or two doses of investigational TIV or control vaccine, at 21 days after last vaccination, are reported. This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 22 and day 50 (21 days after last vaccination) is =40. |
Day 22 for non-naive/Day 50 for naive | No |
Secondary | Percentages of Vaccine-naive Children Achieving HI Titers =40 After Receiving Two Doses of Investigational TIV or Control Vaccine. | The percentage of 3 to 8 years-old vaccine-naive subjects achieving HI titers =40, after receiving two doses of investigational TIV or control vaccine. The time frame of evaluation was 28 days after first (Day 29) and 21 days after second vaccine dose (Day 50). This criterion according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers =40 is =70%, for each vaccine strain. |
Day 1, Day 29, and Day 50 | No |
Secondary | Percentages of Vaccine-naive Children Achieving Seroconversion in Antibody Titers, After Receiving Two Doses of Investigational TIV or Control Vaccine | The percentages of 3 to 8 years-old vaccine naive children achieving seroconversion or significant increase in HI antibody titers after receiving two doses of investigational TIV or control vaccine, are reported. The time frame of evaluation was 28 days after first (Day 29) and 21 days after the second dose (Day 50). This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 29 and day 50 is =40, for each vaccine strain. |
Day 29 and Day 50 | No |
Secondary | Number of Subjects Reporting Solicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine | The number of 3-17 year old children with solicited local and systemic adverse events and other adverse events, after receiving either one or two doses of investigational TIV as compared to control vaccine are reported. | Day 1 to 7 after vaccination | Yes |
Secondary | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine | The number of 3-17 year old children reporting any unsolicited adverse event and any serious adverse event (SAE) after receiving either one or two doses of investigational TIV and control vaccine are reported. | Day 1 to 180 (non-naive )/Day 1 to 209 (naive) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01180621 -
Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children
|
Phase 2 | |
Completed |
NCT01206686 -
The Effect of Time-Slot Scheduling on Flu Vaccination Rates
|
N/A | |
Recruiting |
NCT06049927 -
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
|
Phase 3 | |
Completed |
NCT04133584 -
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
|
Phase 4 | |
Completed |
NCT05566639 -
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
|
Phase 3 | |
Completed |
NCT01072799 -
Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
|
Phase 2 | |
Completed |
NCT00957996 -
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
|
Phase 3 | |
Completed |
NCT01207232 -
The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates
|
N/A | |
Completed |
NCT04997239 -
A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old
|
Phase 4 | |
Completed |
NCT05512494 -
Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated
|
Phase 4 | |
Completed |
NCT01011582 -
Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
|
N/A | |
Terminated |
NCT00958776 -
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
|
Phase 3 | |
Completed |
NCT00560066 -
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
|
Phase 4 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT04896086 -
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults
|
Phase 1 | |
Completed |
NCT01344057 -
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
|
Phase 2 | |
Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
Completed |
NCT00903552 -
Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)
|
Phase 2 | |
Completed |
NCT05827068 -
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05415462 -
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
|
Phase 3 |